Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ALN-6400

Other · developed by ALNYLAM PHARMACEUTICALS

Phase 1/2 Most advanced trial

ALNY Developer

1 Registered trials

What is ALN-6400?

ALN-6400 is an investigational agent administered subcutaneously. It is studied in hereditary hemorrhagic telangiectasia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Hematology
Developer: ALNYLAM PHARMACEUTICALS (ALNY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06659640	Phase 1/2	Hereditary Hemorrhagic Telangiectasia	Active not recruiting	ALNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hereditary Hemorrhagic Telangiectasia

More from ALNYLAM PHARMACEUTICALS

Givosiran FDA approved Lumasiran FDA approved Patisiran FDA approved Vutrisiran FDA approved ALN-2232 Phase 1/2 ALN-4285 Phase 1 ALN-4324 Phase 2 ALN-4915 Phase 1 ALN-5288 Phase 1 ALN-6222 Phase 1 ALN-AGT01 RVR Phase 2 ALN-BCAT Phase 1

Sources

ClinicalTrials.gov NCT06659640

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALNY page.

Follow ALNY, the company behind ALN-6400

See ALNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALNY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z